TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE EUROPE GENE THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET END USER COVERAGE GRID 32
2.8 PRODUCT LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTER FIVE ANALYSIS 42
5 UPDATE ON GERMLINE GENE THERAPY 43
5.1 GERMLINE GENE THERAPY 43
6 EUROPE GENE THERAPY MARKET, MO 44
6.1 DRIVERS 46
6.1.1 NOVEL APPROACHES TO GENE THERAPY 46
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 46
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 47
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 48
6.2 RESTRAINTS 48
6.2.1 HIGH COST OF GENE THERAPY 48
6.2.2 ETHICAL AND SAFETY CONCERNS 49
6.2.3 COMPLEXITY OF GENE THERAPY 49
6.3 OPPORTUNITIES 50
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 50
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 50
6.4 CHALLENGES 51
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 51
6.4.2 LONG-TERM SAFETY AND EFFICACY 51
7 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE 52
7.1 OVERVIEW 53
7.2 VIRAL VECTOR 56
7.2.1 ADENOVIRUS 57
7.2.2 RETROVIRUS 57
7.2.3 LENTIVIRUS 57
7.2.4 ADENO-ASSOCIATED VIRUS 57
7.2.5 VACCINIA VIRUS 57
7.2.6 HERPES SIMPLEX VIRUS 57
7.2.7 OTHERS 57
7.3 NON-VIRAL VECTOR 57
7.3.1 LIPOFECTION 58
7.3.2 INJECTION OF NAKED DNA 58
8 EUROPE GENE THERAPY MARKET, BY METHOD 59
8.1 OVERVIEW 60
8.2 EX-VIVO 63
8.3 IN-VIVO 63
9 EUROPE GENE THERAPY MARKET, BY APPLICATION 65
9.1 OVERVIEW 66
9.2 ONCOLOGICAL DISORDERS 69
9.3 CARDIOVASCULAR DISEASES 69
9.4 INFECTIOUS DISEASES 70
9.5 RARE DISEASES 71
9.6 NUEROLOGICAL DISORDERS 72
9.7 OTHER DISEASES 73
10 EUROPE GENE THERAPY MARKET, BY END USER 74
10.1 OVERVIEW 75
10.2 CANCER INSTITUTES 78
10.3 HOSPITALS 78
10.4 RESEARCH INSTITUTES 79
10.5 OTHERS 80
11 EUROPE GENE THERAPY MARKET, BY REGION 81
11.1 EUROPE 82
11.1.1 GERMANY 88
11.1.2 FRANCE 90
11.1.3 U.K. 92
11.1.4 ITALY 94
11.1.5 SPAIN 96
11.1.6 RUSSIA 98
11.1.7 TURKEY 100
11.1.8 NETHERLANDS 102
11.1.9 BELGIUM 104
11.1.10 SWITZERLAND 106
11.1.11 REST OF EUROPE 108
12 EUROPE GENE THERAPY MARKET, COMPANY LANDSCAPE 109
12.1 COMPANY SHARE ANALYSIS: EUROPE 109
13 COMPANY PROFILES 110
13.1 BIOGEN 110
13.1.1 COMPANY SNAPSHOT 110
13.1.2 REVENUE ANALYSIS 110
13.1.3 COMPANY SHARE ANALYSIS 111
13.1.4 SWOT ANALYSIS 111
13.1.5 PRODUCT PORTFOLIO 112
13.1.6 RECENT DEVELOPMENT 112
13.2 KITE PHARMA 113
13.2.1 COMPANY SNAPSHOT 113
13.2.2 REVENUE ANALYSIS 113
13.2.3 COMPANY SHARE ANALYSIS 114
13.2.4 SWOT ANALYSIS 114
13.2.5 PRODUCT PORTFOLIO 115
13.2.6 RECENT DEVELOPMENT 115
13.3 NOVARTIS AG 116
13.3.1 COMPANY SNAPSHOT 116
13.3.2 REVENUE ANALYSIS 116
13.3.3 COMPANY SHARE ANALYSIS 117
13.3.4 SWOT ANALYSIS 117
13.3.5 PRODUCT PORTFOLIO 118
13.3.6 RECENT DEVELOPMENTS 118
13.4 BRISTOL-MYERS SQUIBB COMPANY. 119
13.4.1 COMPANY SNAPSHOT 119
13.4.2 REVENUE ANALYSIS 119
13.4.3 COMPANY SHARE ANALYSIS 120
13.4.4 SWOT ANALYSIS 120
13.4.5 PRODUCT PORTFOLIO 121
13.4.6 RECENT DEVELOPMENT 121
13.5 OXFORD BIOMEDICA 122
13.5.1 COMPANY SNAPSHOT 122
13.5.2 REVENUE ANALYSIS 122
13.5.3 COMPANY SHARE ANALYSIS 123
13.5.4 SWOT ANALYSIS 123
13.5.5 PRODUCT PORTFOLIO 124
13.5.6 RECENT DEVELOPMENTS 124
13.6 AGC BIOLOGICS 125
13.6.1 COMPANY SNAPSHOT 125
13.6.2 PRODUCT PORTFOLIO 125
13.6.3 RECENT DEVELOPMENT 125
13.7 ANGES, INC 126
13.7.1 COMPANY SNAPSHOT 126
13.7.2 REVENUE ANALYSIS 126
13.7.3 PRODUCT PORTFOLIO 127
13.7.4 RECENT DEVELOPMENT 127
13.8 AMGEN INC. 128
13.8.1 COMPANY SNAPSHOT 128
13.8.2 REVENUE ANALYSIS 128
13.8.3 PRODUCT PORTFOLIO 129
13.8.4 RECENT DEVELOPMENT 129
13.9 BLUEBIRD BIO, INC. 130
13.9.1 COMPANY SNAPSHOT 130
13.9.2 PRODUCT PORTFOLIO 130
13.9.3 RECENT DEVELOPMENT 130
13.10 CHIESI FARMACEUTICI S.P.A 131
13.10.1 COMPANY SNAPSHOT 131
13.10.2 REVENUE ANALYSIS 131
13.10.3 PRODUCT PORTFOLIO 132
13.10.4 RECENT DEVELOPMENT 132
13.11 DENDREON PHARMACEUTICALS LLC 133
13.11.1 COMPANY SNAPSHOT 133
13.11.2 PRODUCT PORTFOLIO 133
13.11.3 RECENT DEVELOPMENT 133
13.12 ENZYVANT THERAPEUTICS GMBH 134
13.12.1 COMPANY SNAPSHOT 134
13.12.2 RODUCT PORTFOLIO 134
13.12.3 RECENT DEVELOPMENT 134
13.13 FERRING B.V. 135
13.13.1 COMPANY SNAPSHOT 135
13.13.2 PRODUCT PORTFOLIO 135
13.13.3 RECENT DEVELOPMENT 135
13.14 JANSSEN PHARMACEUTICALS, INC. 136
13.14.1 COMPANY SNAPSHOT 136
13.14.2 PRODUCT PORTFOLIO 136
13.14.3 RECENT DEVELOPMENT 136
13.15 MALLINCKRODT. 137
13.15.1 COMPANY SNAPSHOT 137
13.15.2 REVENUE ANALYSIS 137
13.15.3 PRODUCT PORTFOLIO 138
13.15.4 RECENT DEVELOPMENT 138
13.16 ORCHARD THERAPEUTICS PLC. 139
13.16.1 COMPANY SNAPSHOT 139
13.16.2 REVENUE ANALYSIS 139
13.16.3 PRODUCT PORTFOLIO 140
13.16.4 RECENT DEVELOPMENT 140
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 141
13.17.1 COMPANY SNAPSHOT 141
13.17.2 PRODUCT PORTFOLIO 141
13.17.3 RECENT DEVELOPMENT 141
13.18 SIBONO 142
13.18.1 COMPANY SNAPSHOT 142
13.18.2 PRODUCT PORTFOLIO 142
13.18.3 RECENT DEVELOPMENT 142
13.19 SPARK THERAPEUTICS, INC. 143
13.19.1 COMPANY SNAPSHOT 143
13.19.2 PRODUCT PORTFOLIO 143
13.19.3 RECENT DEVELOPMENT 143
13.20 UNIQURE NV. 144
13.20.1 COMPANY SNAPSHOT 144
13.20.2 REVENUE ANALYSIS 144
13.20.3 PRODUCT PORTFOLIO 145
13.20.4 RECENT DEVELOPMENT 145
14 QUESTIONNAIRE 146
15 RELATED REPORTS 149

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.